[go: up one dir, main page]

MX2009003921A - Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b. - Google Patents

Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b.

Info

Publication number
MX2009003921A
MX2009003921A MX2009003921A MX2009003921A MX2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A
Authority
MX
Mexico
Prior art keywords
reduction
omega
levels
fatty acids
apo
Prior art date
Application number
MX2009003921A
Other languages
English (en)
Inventor
Robert A Shalwitz
Roelof M L Rongen
Douglas Kling
Ralph T Doyle Jr
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of MX2009003921A publication Critical patent/MX2009003921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos de utilizar una administración combinada o una dosis unitaria de una combinación de un agente dislipidémico y ácidos grasos omega-3 para la reducción de los niveles de apolipoproteína-B; los métodos son especialmente útiles en el tratamiento de pacientes con hipercolesterolemia, hipertrigliceridemia, deslipidemia mixta, enfermedad cardiaca coronaria (CHD), enfermedad vascular, enfermedad aterosclerótica y condiciones relacionada y para la prevención o reducción de eventos cardiovasculares, cardiacos y vasculares.
MX2009003921A 2006-10-10 2007-10-10 Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b. MX2009003921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85028006P 2006-10-10 2006-10-10
PCT/US2007/021631 WO2008045465A1 (en) 2006-10-10 2007-10-10 Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels

Publications (1)

Publication Number Publication Date
MX2009003921A true MX2009003921A (es) 2009-08-31

Family

ID=39283166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003921A MX2009003921A (es) 2006-10-10 2007-10-10 Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b.

Country Status (10)

Country Link
EP (1) EP2089014A4 (es)
JP (1) JP2010505956A (es)
KR (1) KR20090080070A (es)
CN (2) CN101553221A (es)
AU (1) AU2007307007A1 (es)
BR (1) BRPI0719182A2 (es)
CA (1) CA2672919A1 (es)
EA (2) EA018734B1 (es)
MX (1) MX2009003921A (es)
WO (1) WO2008045465A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2008088415A1 (en) * 2006-10-18 2008-07-24 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids for reduction of lp-pla2 levels
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
EP2395991B1 (en) 2009-02-10 2013-05-29 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CA2759284C (en) 2009-04-29 2016-06-21 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
MX338324B (es) 2009-06-15 2016-04-12 Amarin Pharma Inc Composiciones y metodos para reducir trigliceridos sin elevar los niveles de ldl-c en un sujeto en terapia de estatina concomitante.
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
SG10201703867RA (en) 2012-06-29 2017-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014034871A1 (ja) * 2012-08-30 2014-03-06 株式会社 三和化学研究所 脂質異常症の予防又は治療薬
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101967970B1 (ko) * 2014-02-05 2019-04-10 미쓰비시 타나베 파마 코퍼레이션 심장혈관 질환의 치료 또는 예방에서 사용하기 위한 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 저해인자 및 상기 저해인자를 포함하는 약학적 조성물
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170643A1 (en) * 1999-10-26 2003-09-11 Edward Fisher Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes
WO2006062748A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
MX2008000915A (es) * 2005-07-18 2008-04-04 Reliant Pharmaceuticals Inc Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.

Also Published As

Publication number Publication date
EP2089014A4 (en) 2009-12-09
JP2010505956A (ja) 2010-02-25
EP2089014A1 (en) 2009-08-19
CA2672919A1 (en) 2008-04-17
EA200970359A1 (ru) 2009-10-30
EA200970360A1 (ru) 2009-10-30
CN101553221A (zh) 2009-10-07
CN101553220A (zh) 2009-10-07
WO2008045465A1 (en) 2008-04-17
BRPI0719182A2 (pt) 2014-10-21
AU2007307007A1 (en) 2008-04-17
EA018734B1 (ru) 2013-10-30
KR20090080070A (ko) 2009-07-23

Similar Documents

Publication Publication Date Title
MX2009003921A (es) Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b.
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
WO2006062748A3 (en) Omega-3 fatty acids and dyslipidemic agent for lipid therapy
EP2014292A3 (en) Fenoldopam for treatment of acute renal failure
EP2392363A3 (en) Drug coated expandable devices
NZ541593A (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
EP2392364A3 (en) Rapamycin coated expandable devices
ATE297723T1 (de) Pharmazeutische zusammensetzung enthaltend ein 5- aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
JP2007523049A5 (es)
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
MX2007011031A (es) Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos.
WO2003072024A3 (en) Methods of treating vascular disease
MY138301A (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
GB0410266D0 (en) Treatment of apoptosis
EE05556B1 (et) 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
EP2283837A3 (en) Docosahexaenoic acid for treating subclinical inflammation
CA2534202A1 (en) Lipid glycerides for the treatment of neurodegenerative conditions involving demyelination
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
JP2005511619A5 (es)
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
PL368572A1 (en) Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
EP1664775A4 (en) COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME
HUP0301451A3 (en) Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies